This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Nanjing China-Australia Institute of Translational Medicine Co. Ltd.. Active years: 2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2023
Title: Renxiang Tan: Innovator in Cancer Treatment
Introduction
Renxiang Tan is a notable inventor based in Jiangsu, China. He has made significant contributions to the field of cancer treatment through his innovative research and development of small-molecule inhibitors.
Latest Patents
Renxiang Tan holds a patent for the use of AURKB small-molecule inhibitors for the treatment of non-small cell lung cancer. This patent discloses the use of a small-molecule AURKB inhibitor directed to a diindolylmethane compound, which can be a solvate, a N-oxide, or a pharmaceutically acceptable salt thereof. This advancement holds promise for improving treatment options for patients suffering from this type of cancer.
Career Highlights
Renxiang Tan is associated with the Nanjing China-Australia Institute of Translational Medicine Co. Ltd. His work at this institute emphasizes the importance of translational medicine in developing effective therapies for various diseases, particularly cancer.
Collaborations
Renxiang Tan collaborates with esteemed colleagues such as Quan Zhao and Yadong Wang. Their combined expertise enhances the research efforts at the institute and contributes to the advancement of cancer treatment methodologies.
Conclusion
Renxiang Tan's innovative work in developing small-molecule inhibitors represents a significant step forward in the fight against non-small cell lung cancer. His contributions, along with his collaborations, are paving the way for new therapeutic options in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile